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Background: The combination of methotrexate and the anti-
tumour necrosis factor a (TNFa) antibody infliximab is a very
effective treatment for rheumatoid arthritis (RA). However, a
proportion of patients are not responsive to this treatment.
Inefficacy may represent a TNFa independent disease or
insufficient drug at the site of action.
Case report: A patient with RA resistant to repeated high
dose infliximab infusions and intra-articular infliximab into
an inflamed knee is described. No beneficial clinical effect
was observed. Pre-injection arthroscopic biopsy of the study
knee demonstrated TNFa staining but also confirmed the
presence of lymphotoxin a (LTa or TNFb) on immunohisto-
chemistry. Subsequent treatment with etanercept (which
blocks LTa as well as TNFa) resulted in clinical remission of
disease.
Conclusion: This case suggests that resistance to TNF
blockade may occur when TNFa is not the dominant
inflammatory cytokine and suggests that LTa may have a
pathogenic role in RA.
T
he combination of methotrexate and the anti-tumour
necrosis factor a (TNFa) monoclonal antibody infliximab
has proved very beneficial in the treatment of rheuma-
toid arthritis (RA). However, about 35% of patients do not
achieve good clinical improvement.1 The reason(s) for this
lack of clinical response to TNFa blockade are unclear.
Possible reasons include inadequate levels of drug reaching
the primary site of disease or pathophysiological subsets of
RA, where the predominant cytokine driving inflammation is
not TNFa. We report on a patient who failed to respond to
both high dose infliximab infusions and intra-articular (IA)
infliximab but responded to the alternative TNFa blocking
drug etanercept. This case offers new insight into the causes
for anti-TNFa non-response.
CASE REPORT
A 55 year old woman presented with a 4 month history of
polyarthritis predominantly affecting hands, wrists, knees,
and feet. She had a history of hypothyroidism and was a
cigarette smoker with no family history of RA. Her drug
treatment was diclofenac 75 mg slow release formulation
twice daily, thyroxine 50 mg daily, and hormone replacement
therapy (oestradiol 2 mg and norethisterone acetate 1 mg).
She had 300 minutes of early morning stiffness (EMS) and
on examination had a tender joint count (TJC) of 33 and a
swollen joint count (SJC) of 9. Conventional radiography of
the hands and feet demonstrated peri-articular soft tissue
swelling and osteopenia but no radiographic erosions.
Magnetic resonance imaging of her metacarpophalangeal
joints confirmed synovitis. She was rheumatoid factor
positive, HLA-DR4 positive, had a C reactive protein (CRP)
level of 48 mg/l, and normal thyroid function tests. On the
basis of above she was diagnosed as having RA.
After giving informed consent, the patient entered into a
research ethics committee approved study employing high
dose anti-TNF blockade in patients with early, poor prognosis
RA.2 In accordance with the study protocol treatment was
started with methotrexate 7.5 mg once weekly, folic acid
5 mg twice weekly, and infusions of infliximab 10 mg/kg at
weeks 0, 2, 6, 10 and then 8 weekly. By week 12 she had no
improvement, with EMS 300 minutes, TJC 26, SJC 13, and
CRP 41 mg/l. In an attempt to induce significant response the
patient underwent a further series of four high dose
infliximab infusions at similar time intervals. Over this
6 month period the methotrexate dose was increased from
7.5 mg to 20 mg once weekly. After 6 months of treatment
she had EMS 300 minutes, TJC 20, SJC 16, and CRP 125 mg/l.
Because she was clearly not responding she was withdrawn
from the study.
At withdrawal, her left knee was aspirated and injected
with 80 mg of methylprednisolone and she was given 120 mg
methylprednisolone intramuscularly. Her left knee had an
excellent clinical response to the IA corticosteroid. Despite
this she then continued to have very active disease in most of
her other joints. As her right knee continued to be painful
and swollen she underwent an arthroscopy in March 2000.
This demonstrated typical RA findings of moderate synovial
membrane villous formation and marked vascularity. Five
weeks after this procedure her arthroscopic portals were
healed but there was no change in her disease state,
including persistent symptoms and signs in her right knee.
To examine the TNFa resistance, IA infliximab was given.
Previous reports have demonstrated the effectiveness of IA
TNF blocking agents both locally and systemically.3 The right
knee was injected with 70 mg (in 7 ml solution) of inflixi-
mab. The patient was reviewed daily over the next 5 days and
no adverse event was recorded. However, the patient reported
no change in pain in the right knee and there was no change
in the effusion present. At day 5 the knee was aspirated and
80 mg of IA methylprednisolone was injected. The knee had
an excellent clinical response. With the patient continuing to
have very active disease, sulfasalazine and hydroxychloro-
quine were added to her second line treatment (sulfasalazine
dose increased to 1 g daily over 2 weeks). The following
month sulfasalazine was stopped owing to gastrointestinal
side effects. Her methotrexate dose was consequently
increased to 25 mg once weekly (over 4 weeks).
The patient continued to show an unacceptable level of
disease activity. Consequently, hydroxychloroquine was
stopped and treatment was started with etanercept sub-
cutaneously 25 mg twice weekly. By week 12 of the
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etanercept treatment a dramatic symptomatic and clinical
response was observed. She had no EMS and on examination
TJC 2, SJC 1, and normal CRP. ‘‘Good’’ EULAR and ACR50
responses were achieved. By 9 months her ACR response had
improved to ACR70. She has continued to be in clinical
remission for over 2K years.
Synovial membrane biopsy specimens obtained from
arthroscopy were embedded at optimum cutting temperature
on cold hexane, snap frozen, and stored at 280 C˚. Cryostat
sections (3 mm and 4 mm thick) were mounted on superfrost
slides (Surgipath) and dried overnight at 37 C˚. Sections were
fixed for 20 minutes in acetone before incubating with
monoclonal antibodies anti-TNFa (monoclonal mouse IgG1
clone 28401 R&D Systems) and anti-lymphotoxin a (LTa)
(monoclonal mouse IgG1 clone 5802.21 R&D Systems) for
1 hour. A standard staining procedure using ChemMate
(DAKO) was used. Endogenous peroxidase activity was
blocked for 10 minutes. Secondary biotinylated antibody
was added and incubated for 30 minutes, followed by
addition of horseradish peroxidase conjugated avidin-biotin
complex for another 30 minutes. 3,39-Diaminobenzidine was
used to develop colour and was terminated with serial
washings at 10–15 minutes. The slides were counterstained
in haematoxylin (Sigma), dehydrated in ethanol and xylene,
and then mounted.
Arthroscopic inspection disclosed typical RA synovitis, with
villous proliferation. Histology confirmed dense cellular
infiltration. Expression of TNFa was seen in the lining and
sublining layers. Staining for LTa, however, was also positive
again in both the lining and sublining layers (fig 1). The
positive control used was another patient with RA with no
previous exposure to biological agents.
DISCUSSION
This report presents a patient with recent onset RA who
deteriorated while receiving repeated high dose intravenous
infusions, flared after IA infliximab but who showed a
dramatic response (achieving remission) to etanercept, an
alternative TNFa blocking treatment. Infliximab is a chimeric
monoclonal antibody composed of the variable region of
mouse anti-human TNFa antibody fused to human IgG1.
Infliximab binds and neutralises both soluble and mem-
brane-bound TNFa and can lyse cells bearing the latter
through complement activation or antibody dependent,
cell mediated cytotoxicity. Etanercept is a dimeric TNF
receptor:IgG1 fusion protein that neutralises both TNFa
and (unlike infliximab) LTa, but does not possess the
cytotoxic effect in vitro. The contrasting effects of etanercept
following infliximab raises various questions about the
complex issue of non-response.
Figure 1 Panels (A) and (D) are the negative controls for the study patient and positive control respectively. Panels (B) and (E) demonstrate TNFa
expression detected with anti-TNFa monoclonal mouse IgG1 clone 28401 in the study patient and positive control, respectively. Panels (C) and (F)
demonstrate LTa expression detected with anti-LTa monoclonal mouse IgG1 clone 5802.21 in the study patient and positive control, respectively.
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A number of factors can be considered, the first being
whether the response or non-response is a product of the
current scoring tools used. Both the total lack of response
with infliximab and the degree of response seen with
etanercept were dramatic and at the extreme; the differences
could not be explained by an artefact of measurement. Low
serum drug levels might also contribute to a diminished
response but would explain neither failure of response nor
the flare of disease as seen here. Furthermore, the admin-
istration of an intravenous, high dose drug with a loading
regimen is likely to ensure appropriate serum levels, avoiding
potential pharmacokinetic issues. Another reason cited for
infliximab non-response is the formation of human anti-
chimeric antibodies (HACAs). Again we do not believe our
case represents this primarily for two reasons. Firstly, with
HACAs a clinical response is initially seen, which is later lost.
As stated above, our patient failed to show any signs of
improvement with high dose infliximab at any time includ-
ing immediately after the first infusion. Secondly, the knee
joint was treated with intra-articular infliximab. The inflix-
imab dose given would overwhelm any HACAs present, yet
this injection produced a flare of disease. As none of these
possible explanations seem likely this suggests that other
cytokines within the complex network may possess a
pathogenic role. The presence of LTa staining in the pre-
injection synovial biopsy specimen of our patient may be
relevant to explaining the subsequent outcome.
Evidence suggests that chronic inflammation has many of
the characteristics of lymphoid organ neogenesis, and that
LTa seems to have a crucial role in both. LTa is a member of
the TNF family, also known as TNFb.4 It binds to TNFR1
(p55) and TNFR2 (p75). Knockout mice models have
demonstrated the crucial role of LTa in lymphoid organ
development.5 6 LTa, however, also exhibits proinflammatory
effects and induces inflammation in in vivo studies of
transgenic mice, confirming earlier in vitro studies.7 8
This is the first report of such diametrically opposed
responses to infliximab and etanercept. The detection of
synovial LTa (as well as TNFa) expression raises the
interesting possibility that LTa has at least a partial role in
disease drive and pathogenesis. To add further weight to this
concept further synovial studies correlating LTa and TNFa
expression with response and non-response to infliximab are
required. The case, however, epitomises the phenomenon of
true resistance to infliximab, prompting the need for further
investigation.
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